Company Announcement no. 5/2009 To: OMX Nordic Exchange Hørsholm, Denmark, March 9, 2009 LifeCycle Pharma A/S - Report Pursuant to the Danish Securities Trading Act, Section 28(a) Hørsholm, Denmark, March 9, 2009; Pursuant to the Danish Securities Trading Act, Section 28(a), LifeCycle Pharma A/S (OMX: LCP) is required on a daily basis, to make public transactions in LifeCycle Pharma shares and related securities by persons discharging managerial responsibilities and persons / companies closely associated with these. Name Karin J. Hamberg Reason for reporting EVP & CMO Issuer and ID code/ISIN LifeCycle Pharma A/S / DK0060048148 Type of transaction Purchase of shares Date of transaction March 6, 2009 Relevant market NASDAQ OMX Copenhagen Number of traded securities 5,000 Market value DKK 50,000 For more information, please contact: LifeCycle Pharma A/S Peter Schøtt Knudsen Head of Investor Relations Phone: + 45 2055 3817 Email: PSK@lcpharma.com About LifeCycle Pharma A/S (LCP) Based in Hørsholm, Denmark, with an office in New York, LCP is an emerging specialty pharmaceutical company. Clinical development is the core of LCP's effort to develop a product portfolio which includes products for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. As a fully integrated company, LCP adapts new technologies on a fast commercial timetable. LCP's unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability - at low-scale up costs - not only for a broad spectrum of drugs already on the market but also for new chemical entities. LCP has a cholesterol-lowering product, Fenoglide™, currently on the U.S. market and a diversified near- and medium-term pipeline with four product candidates in clinical trials and a number of projects in preclinical development. LCP is listed on NASDAQ OMX Copenhagen under the trading symbol (OMX: LCP). For further information, please visit www.lcpharma.com
LifeCycle Pharma A/S - Report Pursuant to the Danish Securities Trading Act, Section 28(a)
| Source: Veloxis Pharmaceuticals A/S
Attachments
